VEC.L Share News (VEC)

VEC.L Information

There is currently no data for VEC

Vectura and Novartis win FDA approval for COPD combo

Fri, 30th Oct 2015 08:09

(ShareCast News) - Vectura and giant Swiss partner Novartis have received US drug regulator approval for their combination treatment for patients with chronic obstructive pulmonary disease (COPD), triggering a sizeable milestone payment for the UK company.The FTSE 250 drug developer and project partner Novartis were given the green light by the US Food and Drug Administration (FDA) for the new dual combination bronchodilator Utibron Neohaler and the stand-alone monotherapy Seebri Neohaler.Utibron and Seebri are now approved for the long-term maintenance treatment of airflow obstruction in patients with (COPD), including chronic bronchitis and/or emphysema.The approval triggers a $22.5m milestone payment from Novartis to Vectura, as part of their agreement.Novartis, which elsewhere in the world saw sales of these products grew 174% to $297m in the first nine months of 2015, expects that Utibron Neohaler and Seebri Neohaler will be available in the US in the first quarter of 2016.Nearly 27m people in the US are affected by COPD, which ranks as the third leading cause of death in the US and is a major cause of serious long-term disability."The launches of Novartis' Ultibro Breezhaler and Seebri Breezhler ex-US have demonstrated the effectiveness of these products and the need for new treatment options for patients with COPD in the US," said Vectura chief executive James Ward-Lilley.He added: "Once launched, the products will bring a new royalty stream for Vectura and we look forward to confirmation from our partner in due course on their plans for the commercialisation of these products."Analysts at N+1Singer said the US FDA approval of Vectura's key COPD programmes was "an expected but very positive development. We are excited about the prospects of the LABA/LAMA class and believe that Novartis' Utibron is well placed to gain a leading share of the market alongside GSK's Anoro".Separately, Vectura announced that a €0.75m cash milestone had been triggered from partner Sandoz through the successful achievement of a further development milestone associated with asthma drug VR632 in the EU.VR632 is a generic, inhaled combination therapy for asthma/COPD delivered using Vectura's proprietary dry powder inhaler and formulation technology.

More News

19 Apr 2018 12:53

hVIVO CEO Steps Down In Favour Of Executive Chair As Loss Narrows

LONDON (Alliance News) - Clinical development and drug discovery business hVIVO PLC said Thursday its loss narrowed in 2017 as Chief Executive Kym Denny stepped aside for Executive Chairman Trevor

3 Apr 2018 08:41

EUROPE RESEARCH ROUNDUP-Aevis Victoria, Martela Oyj, Mediaset

April 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Aevis Victoria, Martela Oyj and Mediaset, on Tuesday. HIGHLIGHTS * Aevis SA

23 Mar 2018 18:23

DIRECTOR DEALINGS: Vectura Non-Executive Juliet Thompson Buys Shares

LONDON (Alliance News) - Vectura Group PLC said Friday Non-Executive Director Juliet Thompson bought shares worth GBP36,284 in the pharmaceutical company after

22 Mar 2018 16:16

DIRECTOR DEALINGS: Vectura Chairman, Non-Exec Director Buy Shares

LONDON (Alliance News) - Vectura Group PLC said on Thursday that two directors bought shares in the company on Wednesday.Chairman Bruno Angelici purchased 75,000 shares

21 Mar 2018 08:52

Vectura Delivers "Good" 2017 Results Despite Advair Disappointment

LONDON (Alliance News) - Pharmaceutical firm Vectura Group PLC said Wednesday it delivered a "good" set of 2017 results with underlying profit and revenue growth to

21 Mar 2018 08:31

UPDATE 1-UK's Vectura posts wider 2017 loss, revenue rise

March 21 (Reuters) - British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma for

21 Mar 2018 07:47

UPDATE 1-UK Stocks-Factors to watch on March 21

March 21 (Reuters) - Britain's FTSE 100 index is seen opening up 13 points on Wednesday, according to financial bookmakers, with futures 0.26 pct higher ahead of the cash

21 Mar 2018 07:40

Drugmaker Vectura's 2017 revenue rises 17.2 pct

March 21 (Reuters) - British drugmaker Vectura reported a 17.2 percent rise in 2017 revenue on Wednesday, aided by higher demand for its asthma products Flutiform and Ultibro. The company,

20 Mar 2018 13:21

Legal & General Increases Vectura Stake To 3.7% From Below 3% (ALLISS)

LONDON (Alliance News) - Vectura Group PLC said Tuesday FTSE 100-listed insurer and asset manager Legal & General Group PLC increased its stake in the pharmaceutical firm

14 Mar 2018 16:20

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 15 March Old MutualFull Year ResultsPhoenix GroupFull Year GroupFull 16

12 Mar 2018 10:43

WINNERS & LOSERS SUMMARY: Vectura And Hikma Hurt By US FDA Ruling

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------easyJet, up 2.3% at on

12 Mar 2018 09:43

FTSE 100 lags Europe on miners and energy, Just Eat goes cold

(For a live blog on European stocks, type LIVE/ in an Eikon news window) * FTSE 100 up 0.1 pct * Just Eat hit by DB downgrade * Vectura, Hikma hit by delay to Advair GKN up 12

16 Feb 2017 07:49

Vectura Hits GBP9 Million Royalty Cap Under Skyepharma Legacy Deal

16 Feb 2017 07:06

Vectura's GSK royalties agreements firing on all cylinders

(ShareCast News) - Vectura Group hit its royalty cap on sales of GlaxoSmithKline´s Ellipta range of products in 2016, one year ahead of forecasts. The cap was equivalent to £9.0m. The inhaled airways disease-focused business was also set to record £5.4m of 2016 revenues under a separate single digi

8 Feb 2017 13:49

UPDATE 1-Weak pound buoys GSK but drugmaker warns on 2017 generic threat

* 2017 core EPS seen flat-lower if mid-year generic Advair * Current exchange rates would lift 2017 sterling EPS 9 pct * Q4 2016 core EPS 26.1 pence vs consensus forecast 25.0p (Adds CEO comments, shares, background on new CEO) By Ben Hirschler LONDON, Feb 8 (Reuters) -

Latest Share Chat

VEC.L Share News (VEC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Vectura and Novartis win FDA approval for COPD combo

Login to your account

Quickpicks are a member only feature

Login to your account